

Supporting Information

Pd-catalyzed dehydrogenative cross-coupling of pyridine-*N*-oxides with uracils

Ebrahim Kianmehr,^a* Masoud Rezaeefard,^a Mehran Rezazadeh Khalkhali^a and Khalid Mohammed Khan^b

^aSchool of Chemistry, College of Science, University of Tehran, Tehran, Iran. E-mail:
kianmehr@khayam.ut.ac.ir

^bH. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan


1) General remarks.....	S2
2) Reduction of 2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-methylpyridine 1-oxide	S2
3) General Procedure: Pd-catalyzed dehydrogenative cross-coupling of pyridine- <i>N</i> -oxides with uracils.....	S3
4) Preparation and characterization of products.....	S3-S11
5) ¹ H and ¹³ C NMR spectra	S12-S43

General remarks:

Glassware was flame-dried. Solvents, Palladium acetate (98%), Ag₂CO₃, pyridine derivatives were purchased from Merck. All other commercially available reagents were utilized as received without purification. Thin layer chromatography (TLC) analysis was performed using Silicycle precoated TLC plates (silica gel 60 F₂₅₄). The products were purified by preparative column chromatography on silica gel (0.063-0.200 mm; Merck). IR Spectra: Shimadzu FT-IR-4300 spectrometer; in cm⁻¹. ¹H and ¹³C-NMR Spectra: were recorded on Bruker DRX -500, 400, 300 and 250-Advance instrument; in CDCl₃ at 500.1, 400.1, 300.1, 250.1, 125.7, 100, 75.4 and 62.5 MHz, resp; δ in ppm, J in Hz. EI-MS (70 eV): HP 5973 GC-MS instrument; in m/z. Melting points: Electrothermal 9200 apparatus.

Reduction of 2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-methylpyridine 1-oxide (7b) to 3-butyl-5-(4-methylpyridin-2-yl)-1-pentylpyrimidine-2,4(1H,3H)-dione (8)

To a stirred mixture of 7b (331 mg, 1.00 mmol) in toluene (10.0 mL) was added PCl₃ (175 μL, 2.00 mmol) dropwise. The reaction mixture was stirred for 120 min at room temperature. Saturated solution of NaHCO₃ (20 mL) was added and then stirred for additional 15 min. The aqueous layer was then washed with CH₂Cl₂ (20 mL × 3). The combined organic layers were dried over sodium sulphate and filtered, and concentrated in *vacuo*. Purification by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 8 (300 mg, 95%) as a light yellow oil.




3-butyl-5-(4-methylpyridin-2-yl)-1-pentylpyrimidine-2,4(1H,3H)-dione (8)

¹H-NMR (250 MHz, CDCl₃): δ = 8.37 (d, J = 4.7 Hz, 1H), 8.32 (s, 1H), 8.21 (s, 1H), 7.01 (m, 1H), 4.05 (t, J = 7.5 Hz, 2H), 3.87 (t, J = 7.5 Hz, 2H), 2.38 (s, 3H), 1.76-1.67 (m, 4H), 1.46-1.39 (m, 4H), 0.97 (m, 6H). ¹³C-NMR (62.89 MHz, CDCl₃): δ = 161.9 (Cq), 150.8 (Cq), 148.6 (CH), 147.8 (Cq), 143.6 (CH), 123.7 (CH), 123.2 (CH), 111.5 (Cq), 50.1 (CH₂), 41.6 (CH₂), 31.2 (CH₂), 29.7 (CH₂), 21.3 (CH₃), 20.3 (CH₂), 19.8 (CH₂), 13.8 (CH₃), 13.6 (CH₃). IR (KBr): 2954, 2926, 2866, 1698, 1647, 1599, 1477, 1450, 1371, 853, 759 cm⁻¹. MS (EI) m/z (relative intensity): 329 (15) [M⁺], 315 (48), 300 (61), 245 (28), 217 (57), 159 (27), 119 (39), 92 (30). Anal. Calcd. for C₁₈H₂₅N₃O₂: C, 68.54; H, 7.99; N, 13.32; Found: C, 68.62; H, 7.96; N, 13.35.


General Procedure: Pd-catalyzed dehydrogenative cross-coupling of pyridine-N-oxides with uracils

A 10 ml microwave vial equipped with a magnetic stirring bar and septum was flame-dried and then cooled . The vial was then charged with pyridine N-oxide (**5a**) (285 mg, 3 mmol), 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol), Ag₂CO₃ (827 mg, 3 mmol), Pd(OAc)₂ (23 mg, 10 mol %), pyridine (79 mg, 1 mmol) and 1,4-dioxane (4 mL). The vial was then sealed and immersed in an oil bath, which was preheated at 140 °C, for 18 h. After this time the reaction mixture was cooled to room temperature and then diluted with chloroform (10 mL). The mixture was washed with water (5 mL), and the aqueous phase was extracted with chloroform (10 mL). The organic extracts were dried over sodium sulphate and filtered. Concentration of the solution by rotary evaporation under reduced pressure gave a residue which was purified by using column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **3w** (272 mg, 82%) as a brown oil.




2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide (7a)

¹H-NMR (300 MHz, CDCl₃): δ = 8.94 (s, 1H), 8.22 (d, *J* = 6.3 Hz, 1H), 7.93 (d, *J* = 8.1 Hz, 1H), 7.25 (t, *J* = 7.5 Hz, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 3.95 (t, *J* = 7.5 Hz, 2H), 3.80 (t, *J* = 7.5 Hz, 2H), 1.68 (quintet, *J* = 7.2 Hz, 2H), 1.57 (quintet, *J* = 8.1 Hz, 2H), 1.37-1.30 (m, 4H), 0.88 (m, 6H). ¹³C-NMR (75 MHz, CDCl₃): δ = 161.3 (C_q), 150.4 (C_q), 146.5 (CH), 141.6 (C_q), 140.0 (CH), 128.3 (CH), 125.7 (CH), 123.8 (CH), 103.0 (C_q), 50.4 (CH₂), 41.8 (CH₂), 31.1 (CH₂), 29.5 (CH₂), 20.2 (CH₂), 19.7 (CH₂), 13.7 (CH₃), 13.6 (CH₃). IR (KBr): 2956, 2871, 1700, 1637, 1551, 1454, 1369, 1295, 1178, 855, 821, 761 cm⁻¹. MS (EI) *m/z* (relative intensity): 317 (50) [M⁺], 300 (100), 275 (50), 258 (40), 219 (20), 201 (20), 159 (95), 131 (30), 119 (20), 92 (35), 78 (47). Anal. Calcd. for C₁₇H₂₃N₃O₃: C, 64.33; H, 7.30; N, 13.24; Found: C, 64.32; H, 7.28; N, 13.20.



2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-methylpyridine 1-oxide


(7b): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 4-methylpyridine 1-oxide (**5b**) (327 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7b** (259 mg, 78%) as a brown solid (M.p.: 79–81 °C). ¹H-NMR (300 MHz, CDCl₃): δ = 8.90 (d, *J* = 5.7 Hz, 1H), 8.02 (t, *J* = 6.3 Hz, 1H), 7.67 (m, 1H), 6.85 (m, 1H), 3.86 (m, 2H), 3.71 (m, 2H), 2.22 (d, *J* = 4.5 Hz, 3H), 1.60 (m, 2H), 1.49 (m, 2H), 1.26 (m, 4H), 0.83 (m, 6H). ¹³C-NMR (75 MHz, CDCl₃): δ = 161.3 (C_q), 150.3 (C_q), 146.5 (CH), 140.5 (C_q), 139.2 (CH), 137.0 (C_q), 128.5 (CH), 124.6 (CH), 103.0 (C_q), 50.2 (CH₂), 41.7 (CH₂), 31.1 (CH₂), 29.5 (CH₂), 20.4 (CH₃), 20.2 (CH₂), 19.6 (CH₂), 13.7 (CH₃), 13.6 (CH₃). IR (KBr): 2959, 2868, 1703, 1642, 1449, 1373, 1449, 1373, 1295, 1173, 825, 784, 760 cm⁻¹. MS (EI) *m/z* (relative intensity): 331 (13) [M⁺], 314 (65), 289 (20), 272 (45), 258 (10), 233 (17), 173 (100), 159 (20), 145 (73), 133 (40), 106 (70), 92 (100), 77 (45). Anal. Calcd. for C₁₈H₂₅N₃O₃: C, 65.23; H, 7.60; N, 12.68; Found: C, 65.38; H, 7.62; N, 12.68.




2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-methylpyridine 1-oxide

(7c): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 3-methylpyridine 1-oxide (**5c**) (327 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7c** (242 mg, 73%) as a orange solid (M.p.: 75–77 °C). ¹H-NMR (400 MHz, CDCl₃): δ = 8.97 (s, 1H), 8.13 (s, 1H), 7.87 (d, *J* = 8.4 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 4.02 (t, *J* = 7.2 Hz, 2H), 3.86 (t, *J* = 7.2 Hz, 2H), 2.32 (s, 3H), 1.74 (quintet, *J* = 7.2 Hz, 2H), 1.63 (quintet, *J* = 7.6 Hz, 2H), 1.39 (m, 4H), 0.95 (m, 6H). ¹³C-NMR (100 MHz, CDCl₃): δ = 161.5 (C_q), 150.5 (C_q), 146.2 (CH), 139.7 (CH), 138.8 (C_q), 134.5 (C_q), 127.5 (CH), 127.1 (CH), 103.2 (C_q), 50.3 (CH₂), 41.8

(CH₂), 31.2 (CH₂), 29.6 (CH₂), 20.3(CH₃), 19.7 (CH₂), 18.1 (CH₂), 13.8 (CH₃), 13.7 (CH₃). IR (KBr): 3042, 2959, 2870, 1700, 1635, 1451, 1397, 1268, 1121, 1072, 815, 761 cm⁻¹. MS (EI) *m/z* (relative intensity): 331 (16) [M⁺], 314 (50), 272 (24), 258 (7), 233 (24), 201 (27), 173 (100), 159 (17), 149 (90), 133 (25), 106 (42), 92 (48), 77 (50). Anal. Calcd. for C₁₈H₂₅N₃O₃: C, 65.23; H, 7.60; N, 12.68; Found: C, 65.05; H, 7.59; N, 12.71.




2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-ethylpyridine 1-oxide (7d): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 4-ethylpyridine 1-oxide (**5d**) (327 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7d** (277 mg, 80%) as a brown oil. ¹H-NMR (300 MHz, CDCl₃): δ = 8.9 (s, 1H), 8.12 (d, J_H = 6.6 Hz, 1H), 7.73 (s, 1H), 6.94 (d, J = 6.6 Hz, 1H), 3.93 (t, J = 7.2 Hz, 2H), 3.78 (t, J = 7.2 Hz, 2H), 2.58 (q, J = 7.5 Hz, 2H), 1.65 (m, 2H), 1.71-1.54 (m, 4H), 1.18 (t, J = 7.5 Hz, 3H), 0.90 (m, 6H). ¹³C-NMR (75 MHz, CDCl₃): δ = 161.4 (C_q), 150.4 (C_q), 146.6 (CH), 143.4 (C_q), 140.8 (C_q), 139.4 (CH), 127.5 (CH), 123.4 (CH), 103.1 (C_q), 50.3 (CH₂), 41.8 (CH₂), 31.1 (CH₂), 29.5 (CH₂), 27.5 (CH₂), 20.2 (CH₂), 19.7 (CH₂), 14.2 (CH₃), 13.7 (CH₃), 13.6 (CH₃). IR (KBr): 2959, 2869, 1701, 1639, 1452, 1425, 1371, 1292, 1117, 832, 779, 758 cm⁻¹. MS (EI) *m/z* (relative intensity): 345 (45) [M⁺], 328 (88), 303 (72), 286 (45), 272 (8), 187 (100), 173 (10), 159 (50), 91 (20). Anal. Calcd. for C₁₉H₂₇N₃O₃: C, 66.06; H, 7.88; N, 12.16; Found: C, 65.90; H, 7.90; N, 12.13.




4-acetyl-2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide(7e): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 4-acetylpyridine 1-oxide (**5e**) (411 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7e** (263 mg, 73%) as a dark orange solid (M.p.: 95–97 °C). ¹H-NMR (500 MHz, CDCl₃): δ = 8.96 (s, 1H), 8.58 (s, 1H), 8.40 (d, J = 6.5 Hz, 1H), 7.76 (d, J = 5.3 Hz, 1H), 4.03 (t, J = 7.3 Hz, 2H), 3.89 (t, J = 7.1 Hz,

2H), 2.65 (s, 3H), 1.76 (m, 2H), 1.41 (m, 4H), 0.98 (m, 6H). ^{13}C -NMR (125 MHz, CDCl_3): δ = 194.1 (C_{q}), 161.1 (C_{q}), 150.2 (C_{q}), 146.9 (CH), 142.6 (C_{q}), 140.8 (CH), 134.0 (C_{q}), 127.9 (CH), 122.0 (CH), 102.1 (C_{q}), 50.6 (CH_2), 41.9 (CH_2), 31.1 (CH_2), 29.5 (CH_2), 26.4 (CH_3), 20.2 (CH_2), 19.7 (CH_2), 13.7 (CH_3), 13.6 (CH_3). IR (KBr): 3043, 2956, 2869, 1696, 1657, 1459, 1424, 1272, 1237, 857, 524, 776 cm^{-1} . MS (EI) m/z (relative intensity): 359 (75) [M^+], 342 (100), 328 (8), 300 (40), 286 (26), 243 (30), 201 (82), 120 (15). Anal. Calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_4$: C, 63.49; H, 7.01; N, 11.69; Found: C, 63.38; H, 7.03; N, 11.64.




5-acetyl-2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide (7f): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 3-acetylpyridine 1-oxide (**5f**) (411 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1 → 1/4) yielded **7f** (245 mg, 68%) as a Brown solid (M.p.: 102–103 °C). ^1H -NMR (400 MHz, CDCl_3): δ = 9.31 (s, 1H), 8.78 (d, J = 1.6 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.4, 2.0 Hz, 1H), 4.02 (t, J = 7.2 Hz, 2H), 3.88 (t, J = 7.6 Hz, 2H), 2.61 (s, 3H), 1.75 (quintet, J = 7.6 Hz, 2H), 1.63 (quintet, J = 7.6 Hz, 2H), 1.45–1.35 (m, 4H), 0.96 (m, 6H). ^{13}C -NMR (100 MHz, CDCl_3): δ = 193.8 (C_{q}), 161.2 (C_{q}), 150.2 (C_{q}), 147.2 (CH), 144.8 (C_{q}), 140.2 (CH), 132.6 (C_{q}), 127.8 (CH), 124.3 (CH), 102.3 (C_{q}), 50.6 (CH_2), 41.9 (CH_2), 31.2 (CH_2), 29.5 (CH_2), 26.7 (CH_3), 20.2 (CH_2), 19.7 (CH_2), 13.8 (CH_3), 13.6 (CH_3). IR (KBr): 2961, 2872, 1691, 1644, 1501, 1456, 1381, 1288, 1223, 912, 936, 776 cm^{-1} . MS (EI) m/z (relative intensity): 395 (22) [M^+], 342 (80), 328 (5), 300 (34), 286 (15), 243 (17), 201 (100), 120 (15). Anal. Calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_4$: C, 63.49; H, 7.01; N, 11.69; Found: C, 63.56; H, 6.98; N, 11.71.




2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-(ethoxycarbonyl)pyridine 1-oxide (7g): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 3-(ethoxycarbonyl)pyridine 1-oxide (**5g**) (411 mg, 3.00


mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7g** (247 mg, 66%) as a brown solid (M.p.: 124–126 °C). ¹H-NMR (500 MHz, CDCl₃): δ = 9.25 (s, 1H), 8.82 (s, *J* = 1.5 Hz, 1H), 8.15 (d, *J* = 9.0 Hz, 1H), 7.83 (dd, *J* = 9, 1.7 Hz, 1H), 4.39 (q, *J* = 7.1 Hz, 2), 3.99 (t, *J* = 7.5 Hz, 2H), 3.85 (t, *J* = 7.5 Hz, 2H), 1.75–1.67 (m, 2H), 1.62–1.57 (m, 2H), 1.37 (m, 7H), 0.93 (m, 6H). ¹³C-NMR (125 MHz, CDCl₃): δ = 162.8 (C_q), 161.1 (C_q), 150.2 (C_q), 147.2 (CH), 144.8 (C_q), 141.1 (CH), 127.6 (CH), 127.0 (C_q), 125.9 (CH), 102.3 (C_q), 62.1 (CH₂), 50.6 (CH₂), 41.9 (CH₂), 31.1 (CH₂), 29.5 (CH₂), 20.2 (CH₂), 19.7 (CH₂), 14.1 (CH₃), 13.7 (CH₃), 13.6 (CH₃). IR (KBr): 2931, 2049, 1731, 1645, 1607, 1568, 1370, 1020, 945, 772 cm^{−1}. MS (EI) *m/z* (relative intensity): 389 (10) [M⁺], 372 (30), 358 (5), 330 (17), 231 (45), 167 (70), 149 (100). Anal. Calcd. for C₂₀H₂₇N₃O₅: C, 61.68; H, 6.99; N, 10.79; Found: C, 61.46; H, 7.01; N, 10.83.



2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-methoxypyridine 1-oxide (7h): The general procedure A was followed using 1,3-dibutylpyrimidine-2,4(1*H*,3*H*)-dione (**6a**) (224 mg, 1.00 mmol) and 3-methoxypyridine 1-oxide (**5h**) (375 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7h** (296 mg, 85%) as a drak orange solid (M.p.: 70–72 °C). ¹H-NMR (500 MHz, CDCl₃): δ = 8.80 (s, 1H), 8.04 (s, 1H), 7.86 (d, *J* = 9.0 Hz, 1H), 6.96 (d, *J* = 7.5 Hz, 1H), 4.01 (t, *J* = 7.5, Hz, 2H), 3.86 (s, 3H), 3.85 (t, *J* = 7.5 Hz, 2H), 1.74 (m, 2H), 1.62 (m, 2H), 1.40 (m, 4H), 0.96 (m, 6H). ¹³C-NMR (125 MHz, CDCl₃): δ = 161.5 (C_q), 156.1 (C_q), 150.5 (C_q), 145.8 (CH), 135.0 (C_q), 127.9 (CH), 127.6 (CH), 113.8 (CH), 103.1 (C_q), 56.2 (CH₃), 50.3 (CH₂), 41.8 (CH₂), 31.2 (CH₂), 29.6 (CH₂), 20.2 (CH₂), 19.7 (CH₂), 13.7 (CH₃), 13.6 (CH₃). IR (KBr): 3063, 2959, 2930, 1705, 1635, 1513, 1452, 1337, 1300, 1178, 827, 779, 759 cm^{−1}. MS (EI) *m/z* (relative intensity): 347 (80) [M⁺], 330 (100), 288 (45), 274 (10), 231 (17), 189 (85), 175 (10), 161 (36), 108 (20). Anal. Calcd. for C₁₈H₂₅N₃O₄: C, 62.23; H, 7.25; N, 12.10; Found: C, 62.27; H, 7.22; N, 12.09.




2-(1,3-bis(3-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-methylpyridine 1-oxide (7i): The general procedure A was followed using 1,3-bis(3-methylbenzyl)pyrimidine-2,4(1*H*,3*H*)-dione (**6b**) (320 mg, 1.00 mmol) and 4-methylpyridine 1-oxide (**5b**) (327 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1 → 1/4) yielded **7i** (320 mg, 77%) as a yellow solid (M.p.: 118–119 °C). ¹H-NMR (400 MHz, CDCl₃): δ = 9.06 (s, 1H), 8.19 (d, *J* = 6.4 Hz, 1H), 7.74 (d, *J* = 2.0 Hz, 1H), 7.30–6.98 (m, 8H), 6.97 (d, *J* = 2.0 Hz, 1H), 5.19 (s, 2H), 5.01 (s, 2H), 2.37 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H). ¹³C-NMR (100 MHz, CDCl₃): δ = 161.3 (C_q), 150.8 (C_q), 146.6 (CH), 140.7 (C_q), 139.3 (CH), 138.8 (C_q), 138.1 (C_q), 137.9 (C_q), 136.3 (C_q), 135.1 (C_q), 129.4 (CH), 129.3 (CH), 128.99 (CH), 128.96 (CH), 128.8 (CH), 128.5 (CH), 128.3 (CH), 126.0 (CH), 125.3 (CH), 124.9 (CH), 103.6 (C_q), 53.3 (CH₂), 45.1 (CH₂), 21.42 (CH₃), 21.41 (CH₃), 20.5 (CH₃). IR (KBr): 2919, 1738, 1698, 1652, 1445, 1371, 1217, 883, 827, 790 cm⁻¹. MS (EI) *m/z* (relative intensity): 427 (65) [M⁺], 411 (50), 172 (5), 159 (25), 146 (33), 105 (100), 91 (20). Anal. Calcd. for C₂₆H₂₅N₃O₃: C, 73.05; H, 5.89; N, 9.83; Found: C, 73.16; H, 5.90; N, 9.79.




5-acetyl-2-(1,3-bis(3-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide (7j): The general procedure A was followed using 1,3-bis(3-methylbenzyl)pyrimidine-2,4(1*H*,3*H*)-dione (**6b**) (320 mg, 1.00 mmol) and 3-acetylpyridine 1-oxide (**5f**) (411 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1 → 1/4) yielded **7j** (286 mg, 65%) as a yellow solid (M.p.: 129–131 °C). ¹H-NMR (500 MHz, CDCl₃): δ = 9.36 (s, 1H), 8.82 (s, 1H), 8.19 (d, *J* = 8.5 Hz, 1H), 7.83 (m, 1H), 7.29–7.16 (m, 6H), 7.09 (m, 1H), 5.20 (s, 2H), 5.04 (s, 2H), 2.61 (s, 3H), 2.36 (s, 3H), 2.34 (s, 3H). ¹³C-NMR (125 MHz, CDCl₃): δ = 193.5 (C_q), 161.0 (C_q), 150.6 (C_q), 147.3 (CH), 140.5 (CH), 139.0 (C_q), 138.2 (C_q), 136.1 (C_q), 134.7 (C_q), 132.7 (C_q), 129.6 (CH), 129.1 (CH), 129.0 (CH), 128.6 (CH), 128.3 (CH), 128.1 (CH), 126.0 (CH), 125.4 (CH), 103.0 (C_q), 53.6 (CH₂), 45.2 (CH₂), 26.7 (CH₃), 21.4 (CH₃). IR (KBr): 3032, 2922, 1696, 1652, 1586, 1445, 1388,

1284, 1220, 1114, 885, 830, 793 cm⁻¹. MS (EI) *m/z* (relative intensity): 445 (45) [M⁺], 438 (35), 291 (10), 215 (35), 187 (15), 146 (75), 120 (37), 105 (100), 91 (15), 79 (34). Anal. Calcd. for C₂₇H₂₅N₃O₄: C, 71.19; H, 5.53; N, 9.22; Found: C, 71.21; H, 5.54; N, 9.18.




4-acetyl-2-(1,3-bis(3-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide (7k): The general procedure A was followed using 1,3-bis(3-methylbenzyl)pyrimidine-2,4(1*H*,3*H*)-dione (**6b**) (320 mg, 1.00 mmol) and 4-acetylpyridine 1-oxide (**5e**) (411 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7k** (308 mg, 70%) as a orange solid (M.p.: 125–126 °C). ¹H-NMR (250 MHz, CDCl₃): δ = 8.94 (s, 1H), 8.46 (d, *J* = 2.5 Hz, 1H), 8.24 (d, *J* = 5.0 Hz, 1H), 7.66 (m, 1H), 7.27–7.07 (m, 8H), 5.20 (s, 2H), 5.01 (s, 2H), 2.59 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H). ¹³C-NMR (62.89 MHz, CDCl₃) δ = 194.3 (C_q), 161.2 (C_q), 150.7 (C_q), 146.1 (CH), 140.4 (C_q), 139.0 (C_q), 138.2 (C_q), 136.2 (C_q), 134.8 (C_q), 132.1 (C_q), 129.51 (CH), 129.47 (CH), 129.03 (CH), 128.94 (CH), 128.6 (CH), 128.4 (CH), 127.7 (CH), 126.0 (CH), 125.3 (CH), 122.1 (CH), 103.4 (C_q), 53.4 (CH₂), 45.2 (CH₂), 26.4 (CH₃), 21.4 (CH₃). IR (KBr): 2918, 1702, 1644, 1607, 1545, 1446, 1358, 1221, 950, 667 cm⁻¹. MS (EI) *m/z* (relative intensity): 455 (45) [M⁺], 438 (50), 291 (12), 215 (41), 146 (70), 105 (100), 91 (21), 77 (44). Anal. Calcd. for C₂₇H₂₅N₃O₄: C, 71.19; H, 5.53; N, 9.22; Found: C, 71.36; H, 5.53; N, 9.25.




2-(1,3-bis(3-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-(ethoxycarbonyl)pyridine 1-oxide (7l): The general procedure A was followed using 1,3-bis(3-methylbenzyl)pyrimidine-2,4(1*H*,3*H*)-dione (**6b**) (320 mg, 1.00 mmol) and 3-(ethoxycarbonyl)pyridine 1-oxide (**5g**) (501 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7l** (292 mg, 60%) as a orange solid (M.p.: 127–129 °C). ¹H-NMR (500 MHz, CDCl₃): δ = 9.36 (s, 1H), 8.84 (s, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 7.83 (d, *J* = 8.5 Hz, 1H), 7.28–7.15 (m, 7H), 7.10 (s, *J* = 7.5 Hz, 1H), 5.20 (s,

2H), 5.03 (s, 2H), 4.41 (q, $J = 7.0$ Hz, 2H), 2.36 (s, 3H), 2.34 (s, 3H), 1.41 (t, $J = 7.0$ Hz, 3H). ^{13}C -NMR (125 MHz, CDCl_3): δ = 163.2 (C_{q}), 161.1 (C_{q}), 150.7 (C_{q}), 146.9 (CH), 144.6 (C_{q}), 141.1 (CH), 139.0 (C_{q}), 138.2 (C_{q}), 136.2 (C_{q}), 134.8 (C_{q}), 129.5 (CH), 129.0 (CH), 128.6 (CH), 128.4 (CH), 127.7 (CH), 127.2 (C_{q}), 126.0 (CH), 125.8 (CH), 125.4 (CH), 103.0 (C_{q}), 62.2 (CH₂), 53.5 (CH₂), 45.2 (CH₂), 21.4 (CH₃), 14.2 (CH₃). IR (KBr): 2986, 1732, 1703, 1657, 1606, 1548, 1398, 1358, 1218, 1020, 966, 818 cm^{-1} . MS (EI) m/z (relative intensity): 485 (20) [M^+], 468 (13), 245 (10), 217 (17), 146 (64), 105 (100), 91 (33), 77 (41). Anal. Calcd. for $\text{C}_{28}\text{H}_{27}\text{N}_3\text{O}_5$: C, 69.26; H, 5.61; N, 8.65; Found: C, 69.18; H, 5.62; N, 8.63.




2-(1,3-bis(3-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-methylpyridine 1-oxide (7m): The general procedure A was followed using 1,3-bis(3-methylbenzyl)pyrimidine-2,4(*1H,3H*)-dione (**6b**) (320 mg, 1.00 mmol) and 3-methylpyridine 1-oxide (**5c**) (327 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1 → 1/4) yielded **7m** (325 mg, 76%) as a dark orange solid (M.p.: 149–150 °C). ^1H -NMR (250 MHz, CDCl_3): δ = 9.01 (s, 1H), 8.10 (s, 1H), 7.82 (d, $J = 7.5$ Hz, 1H), 7.26–7.05 (m, 8H), 5.17 (s, 2H), 4.99 (s, 2H), 2.33 (s, 3H), 2.32 (s, 3H), 2.29 (s, 3H). ^{13}C -NMR (62.98 MHz, CDCl_3): δ = 161.2 (C_{q}), 150.1 (C_{q}), 145.9 (CH), 139.7 (C_{q}), 138.9 (C_{q}), 138.1 (C_{q}), 136.4 (C_{q}), 135.0 (C_{q}), 134.7 (C_{q}), 129.5 (CH), 129.3 (CH), 129.1 (CH), 128.4 (CH), 128.3 (CH), 127.6 (CH), 127.0 (CH), 126.0 (CH), 125.3 (CH), 103.3 (C_{q}), 53.3 (CH₂), 45.1 (CH₂), 21.4 (CH₃), 18.0 (CH₃). IR (KBr): 3042, 2921, 1701, 1643, 1589, 1499, 1330, 1207, 781, 759 cm^{-1} . MS (EI) m/z (relative intensity): 427 (51) [M^+], 410 (32), 313 (62), 200 (31), 146 (17), 109 (100), 92 (27), 77 (35). Anal. Calcd. for $\text{C}_{26}\text{H}_{25}\text{N}_3\text{O}_3$: C, 73.05; H, 5.89; N, 9.83; Found: C, 72.87; H, 5.91; N, 9.87.




2-(1,3-dibenzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide (7n): The general procedure A was followed using 1,3-dibenzylpyrimidine-2,4(*1H,3H*)-dione (**6c**) (292 mg, 1.00 mmol) and pyridine 1-oxide (**5a**) (285 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1 → 1/4) yielded **7n** (301 mg, 78%) as a dark orange solid (M.p.: 118–120 °C). ^1H -NMR (250 MHz, CDCl_3): δ = 9.18 (s, 1H), 8.23 (d, J =

5.0 Hz, 1H), 7.93 (m, 1H), 7.54-7.11 (m, 12H), 5.21 (s, 2H), 5.04 (s, 2H). ^{13}C -NMR (62.89 MHz, CDCl_3): δ = 161.2 (C_q), 150.8 (C_q), 146.2 (CH), 140.0 (CH), 136.4 (C_q), 135.0 (C_q), 129.13 (CH), 129.10 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 127.8 (CH), 125.5 (CH), 123.9 (CH), 103.8 (C_q), 53.4 (CH₂), 45.1 (CH₂). IR (KBr): 3416, 3066, 1700, 1650, 1694, 1449, 1428, 1375, 1212, 760, 694 cm^{-1} . MS (EI) m/z (relative intensity): 385 (54) [M $^+$], 368 (40), 235 (11), 132 (37), 91 (100), 78 (13), 65 (26). Anal. Calcd. for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}_3$: C, 71.67; H, 4.97; N, 10.90; Found: C, 71.81; H, 4.99; N, 10.87.




4-benzyl-2-(1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyridine 1-oxide


(7o): The general procedure A was followed using **(6a)** (224 mg, 1.00 mmol) and 4-benzylpyridine 1-oxide (**5i**) (555 mg, 3.00 mmol). Purification by column chromatography (*n*-hexane/EtOAc: 1/1→1/4) yielded **7o** (327 mg, 80%) as a yellow oil. ^1H -NMR (250 MHz, CDCl_3): δ = 9.01 (s, 1H), 8.15 (d, J = 6.5 Hz, 1H), 7.87 (d, J = 2.5 Hz, 1H), 7.35-7.17 (m, 5H), 6.90 (m, 1H), 4.01 (m, 4H), 3.84 (t, J = 7.5 Hz, 2H), 1.76-1.61 (m, 4H), 1.46-1.31 (m, 4H), 0.95 (t, J = 7.2 Hz, 6H). ^{13}C -NMR (62.89 MHz, CDCl_3): δ = 161.4 (C_q), 150.4 (C_q), 146.6 (CH), 140.9 (C_q), 140.1 (CH), 139.7 (CH), 138.4 (C_q), 129.0 (CH), 128.9 (CH), 128.3 (CH), 126.9 (CH), 124.1 (CH), 103.1 (C_q), 50.4 (CH₂), 41.8 (CH₂), 40.5 (CH₂), 31.2 (CH₂), 29.6 (CH₂), 20.3 (CH₂), 19.7 (CH₂), 13.8 (CH₃), 13.6 (CH₃). IR (KBr): 2958, 1699, 1648, 1456, 1430, 1354, 1245, 1223, 809, 700 cm^{-1} . MS (EI) m/z (relative intensity): 407 (17) [M $^+$], 390 (22), 329 (41), 252 (30), 215 (30), 143 (100), 105 (47), 77 (32). Anal. Calcd. for $\text{C}_{30}\text{H}_{25}\text{N}_3\text{O}_3$: C, 75.77; H, 5.30; N, 8.84; Found: C, 75.62; H, 5.27; N, 8.87.

S-1 HNMR





161.31
150.40
146.46
141.61
140.03
128.27
125.69
123.79
103.03
50.36
41.78
31.15
30.13
29.53
20.22
19.70
13.74
13.62





S-2 HNMR





Current Data Parameters
NAME Kyamehr
EXPNO 19
PROCNO 1

F2 - Acquisition Parameters
Date 20120516
Time 13.38
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 8
DS 0
SWH 6172.839 Hz
FIDRES 0.183380 Hz
AQ 2.6542580 sec
RG 32
DW 81.000 usec
DE 6.00 usec
TE 300.0 K
D1 6.0000000 sec

==== CHANNEL f1 =====
NUC1 1H
PL 9.00 usec
SF 3.00 dB
SFO1 299.8729987 MHz


F2 - Processing parameters
SI 32768
SF 299.8700027 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





Current Data Parameters
NAME Kyanmehr
EXPNO 18
PROCNO 1




F2 - Acquisition Parameters
Date 20120516
Time 12.17
INSTRUM spect
PROBID 5 mm BBO BB-1H
PULPROG zgpg30
TD 65536
SOLVENT CDCl₃
NS 850
DS 2
SWH 17985.611 Hz
FIDRES 0.274439 Hz
AQ 1.8219508 sec
RG 32768
DW 27.800 usec
DE 6.00 usec
TE 300.0 K
D1 2.0000000 sec
d11 0.0300000 sec
d12 0.00002000 sec



S6 1H

NAME :
EXPNO :
PROCNO :
Date : 2012/07
Time : 10:35
INSTRUM : spect
PROBHD : 5 mm PABBO BB-
PULPROG : TD
TD : 32768
SOLVENT : CCl3
NS : 8
DS : 0
SWH : 6009.615 Hz
FIDRES : 0.183399 Hz
AQ : 2.726347 sec
RG : 80.6
DW : 83.200 us/sec
DE : 6.50 us/sec
TE : 292.8 K
D1 : 6.000000 sec
TDD0 : 1

===== CHANNEL 11 ======
NUC1 : ¹H
P1 : 13.50 usec
PL1 : 0.00 dB
PLW : 11.3034873 W
SF01 : 400.1328410 MHz
SI : 32768
SF : 400.1300000 MHz
WDW : EM
SSB : 0
LB : 0.30 Hz
GB : 0
PC : 1.00



13.662


14 ppm

13.662
13.784
13.795
13.754
20.269
29.576
31.199

41.802
50.359


103.192

127.109
127.559
134.516
138.766
139.753
146.168
150.472
161.452




NAME: S6 13C
EXPTNO: 1
PROCNO: 1
Date: 2012017
Time: 10:59
INSTRUM: spect
PROBHD: 5 mm PABBO BB-
PULPROG: 65326
TD: 2048000
SOLVENT: CDCl3
NS: 328
DS: 0
SWH: 24038.46 Hz
FIDRES: 0.386798 Hz
AQ: 1.363198 sec
RG: 203
DW: 20.800 usec
DE: 6.800 usec
TE: 295.5 K
D1: 2.000000 sec
D11: 0.0300000 sec
TDO: 1

===== CHANNEL 1 =====
NUC1: 13C
P1: 7.60 usec
PL1: 200.0 dB
PL1W: 56.9932510 W
SF01: 100.6228298 MHz
===== CHANNEL 2 =====
NUC2: 1H
CPDPG2: 1H
PCPD2: 65.00 usec
PL2: 0.00 dB
PL12: 16.00 dB
PL13: 16.00 dB
PL2W: 11.30348873 W
PL12W: 0.283393081 W
PL13W: 0.283393081 W
SF02: 400.13166005 MHz
SI: 32768
SF: 100.6227690 MHz
VDW: F.M.
SSB: 100.0 Hz
OB: 0
PC: 1.40






S-4 HNMR




S-4 CNMR



BRUKER

Mr Rezaieefar S7





Current Data Parameters
NAME Dr Kianmehr 8
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date 20120520
Time 11.44
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg
TD 32768
SOLVENT CDCl3
NS 6
DS 0
SWH 8503.401 Hz
FIDRES 0.259503 Hz
AQ 1.9268084 sec
RG 181
DW 58.800 usec
DE 6.50 usec
TE 673.2 K
D1 1.0000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 9.50 usec
PL1 3.00 dB
SFO1 500.13335009 MHz

F2 - Processing parameters
SI 32768
SF 500.1300000 MHz
WDW EM
SSB 0
LB 3.00 Hz
GB 0
PC 12.00








13.637
13.770

13.637
13.770
19.716
20.239
26.749
29.544
31.177
41.925
50.642

102.352



124.256
127.836
132.569
140.259
144.810
147.204
150.222
161.166

193.781



NAME S13-13C
EXPTNO. 1
PROCNO. 1
Date. 2012/01/17
Time. 11:21
INSTRUM. spect
PROBTD. 5 mm PABD BB-
PULPROG. zg399
TD. 65536
SOLVENT. CDD3
NS. 130
DS. 0
SWH. 24038.461 Hz
FIDRES. 0.386738 Hz
AQ. 1.3031988 sec
RG. 203
DW. 20.800 usec
DE. 6.50 Jusec
TE. 285.3 K
TE. 2.0000000 sec
D1. 0.0300000 sec
TDO. 1

===== CHANNEL 1 ======
NUC1: 13C
P1: 7.60 usHC
PL1: 2.00 dB
PLW: 56.6232310 W
SF01: 100.6228289 MHz
===== CHANNEL 2 ======
CPDRG2: wait:16
NUC2: 1H
PCP02: 85.00 usec
PL2: 0.00 dB
PL12: 16.00 dB
PL13: 16.00 dB
PL2W: 11.30343973 W
PL12W: 0.28393081 W
PL13W: 0.28393091 W
SF02: 400.1316.035 MHz
SI: 32768
SF: 100.6127650 MHz
WOW: EM
SSB: 0
LB: 1.00 Hz
GB: 0
PC: 1.40



F2 - Acquisition Parameters


Date	20121128
Time	13:00
INSTRUM	PABBO BB-spect
PROBHD	5 mm PABBO BB-PULPROG
TD	32768
SOLVENT	CDCl ₃
NS	8
DS	0
SWH	9014.423 Hz
FIDRES	0.27598 Hz
AQ	1.8175818 sec
RG	90.5
DW	55.467 usec
DE	6.50 usec
TE	295.8 K
D1	1.5000000 sec
TD0	1

===== CHANNEL f1 =====

NUC1	1H
P1	4.00 usec
PLL	3.00 dB
SFO1	500.1335009 MHz


F2 - Processing parameters

SI	32768
SF	500.1300000 MHz
WDW	EM
SSB	0
LB	0.00 Hz
GB	0
PC	150.00





"Dr Foroumadi10" 18 1 C:\Bruker\TOPSPIN guest


Dr. Foroumadi S18



BRUKER



S-17



Current Data Parameters
NAME EXPNO 102
PROCNO 1

F2 - Acquisition Parameters
Date 20121128
Time 12.14
INSTRUM spect

PROBHD 5 mm PABBO BB-
PULPROG zg
TD 32768
SOLVENT CDCl₃
NS 8
DS 0
SWH 9014.423 Hz
FIDRES 0.275098 Hz
AQ 1.8175818 sec
RG 90.5
DW 55.467 usec
DE 6.50 usec
TE 295.2 K
D1 1.5000000 sec
TDO 1


===== CHANNEL f1 =====

NUC1 ¹H
P1 4.00 usec
PL1 3.00 dB
SFO1 500.1335009 MHz

F2 - Processing parameters

SI 32768
SF 500.1300000 MHz
WDW EM
SSB 0
LB 0.00 Hz
GB 0
PC 20.00







S15 1H

NAME 1
 EXPNO 1
 PROCNO 1
 Date 2012/07/20
 Time 11:29
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG 29
 TD 32768
 SOLVENT CDCl3
 NS 8
 DS 0
 SWH 6009.615 Hz
 FIDRES 0.183399 Hz
 AQ 2.7263477 sec
 RG 25.4
 DW 83.200 usec
 DE 6.60 usec
 TE 292.6 K
 D1 6.000000 sec
 TDO 1

===== CHANNEL 1 =====
 NUC1 1H
 P1 13.50 usec
 PL1 0.00 dB
 PL1W 11.30348873 W
 SF01 400.1329410 MHz
 SI 32768
 SF 400.1300000 MHz
 VDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



S15 13C



NAME 1
EXPNO 1
PROCNO 1
Date 2012017
Time 12:03
INSTRUM spect
PROBHD 5 mm PABBO BB-
TD 2999
B65536
SOLVENT CDCl3
NS 512
DS 0
SWH 24038.461 Hz
FIDRES 0.366798 Hz
AQ 1.3631988 sec
RG 203
DW 20.000 usec
DE 6.50 usec
TE 293.3 K
D1 2.0000000 sec
TDD 0.03000000 sec
J1 1

===== CHANNEL f1 =====
NUC1 13C
P1 7.60 usec
PL1 -2.00 dB
PL1W 56.92932510 W
SF01 100.6226298 MHz
===== CHANNEL f2 =====
CPDPG2 waltz16
NUC2 1H
PCPD2 85.00 usec
P12 0.00 dB
P112 16.00 dB
P113 16.00 dB
P12W 11.30348873 W
P112W 0.28393081 W
PL13W 0.28393081 W
SF02 400.1316002 MHz
SI 32768
SF 100.6127690 MHz
WDM EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

20.546
21.414
21.428

45.125
53.347

103.633
124.938
125.337
125.987
128.355
128.494
128.821
128.966
128.996
129.347
129.463
135.069
136.345
137.983
138.120
138.856
139.351
140.665
146.645
150.842
161.313






0.012

Current Data Parameters
 NAME Dr Foroumadi 9
 EXPNO 14
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20121230
 Time_ 10:23
 INSTRUM PROBHD 5 mm PABBO BB-
 PULPROG 32768
 TD 2g
 SOLVENT CDCl3
 NS 8
 DS 0
 SWH 9014.423 Hz
 FIDRES 0.275098 Hz
 AQ 1.8175818 sec
 RG 181
 DW 55.467 usec
 DE 6.50 usec
 TE 291.1 K
 D1 2.5000000 sec
 TDO 1


===== CHANNEL F1 =====
 NUCL 1H
 P1 4.00 usec
 PLL 3.00 dB
 SF01 500.1335009 MHz






2.610
2.357
2.38




5.044
5.196
5.196
7.095
7.110
7.110
7.156
7.156
7.171
7.171
7.192
7.192
7.200
7.200
7.206
7.206
7.216
7.216
7.232
7.232
7.262
7.262
7.277
7.277
7.278
7.278
7.285
7.285
7.291
7.291
7.360
7.360
8.18
8.31
8.36
8.60
9.07
9.36
9.60
10.01
10.44
11.13
11.50
12.00











F2 - Acquisition Parameters

Date	20130213
Time	8.21
INSTRUM	spec
PROBHD	5 mm PABBO BB-
PULPROG	Zg
TD	32768
SOLVENT	CDCl3
NS	8
DS	0
SWH	9014.423 Hz
FIDRES	0.275098 Hz
AQ	1.8175818 sec
RG	181
DW	55.467 usec
DE	6.50 usec
TE	292.9 K
D1	2.5000000 sec
TDO	1


F2 - Acquisition Parameters

NUC1	1H
P1	4.00 usec
PL1	3.00 dB
SFO1	500.1335009 MHz



===== CHANNEL f1 =====


F2 - Processing parameters

SI	32768
SF	500.1300000 MHz
WDW	EM
SSB	0
LB	3.00 Hz
GB	0
PC	20.00



-163.1702
-161.0659
-150.6588
-146.9402
-144.5802
-141.1236
-138.9705
-136.11705
-134.7653
-129.5043
-129.0340
-128.5770
-127.7464
-127.1640
-126.0246
-125.8447
-125.3769
-103.0272
-62.1830
-53.5376
-45.2033
-21.4067
-14.1638





Current Data Parameters
 NAME gohari
 EXPNO 545
 PROGNO 1

F2 - Acquisition Parameters
 Date_ 20130721
 Time 14:52
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG zgpg
 TD 55536
 SOLVENT CDCl₃
 NS 469
 DS 4
 SWH 15723.271 Hz
 FIDRES 0.235988 Hz
 AQ 2.084098 sec
 RG 13004
 DW 31.800 usec
 DE 6.00 usec
 TE 300.0 K
 D1 4.000000 sec
 D11 0.0500000 sec
 D12 0.0000200 sec

===== CHANNEL f1 =====
 NUC1 13C
 P1 6.50 usec
 PL1 -6.00 dB
 SF01 62.9024320 kHz
 ===== CHANNEL f2 =====
 CPDPRG2 Hahn1216
 NUC2 1H
 PCPD2 80.00 usec
 PL2 -4.00 dB
 PL42 15.00 dB
 PL13 18.00 dB
 SF02 250.131005 MHz

F2 - Processing parameters
 SI 32768
 SF 62.8952401 MHz
 WDR EH
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

1D NMR pilot parameters
 CX 20.00 cm
 F1P 205.116 ppm
 F1 12863.69 Hz
 F2P -4.612 ppm
 F2 -290.07 Hz
 PPGCM 10.5338 ppm/cm
 HZCM 662.68829 Hz/cm

24.387

45.101

53.283

77.534

77.025

76.517

125.299

126.050

127.000

127.604

128.307

128.451

128.961

129.327

129.547

134.656

135.065


136.410

138.081


138.865


139.750

145.907



ppm





Current Data Parameters

NAME	gohari
EXPNO	549
PROCNO	1

F2 - Acquisition Parameters

Date	20130721
Time	17.09
INSTRUM	spect
PROBHD	5 mm QNP 3H/4
PULPROG	Zpg3
TD	65536
SOLVENT	CDCl ₃
NS	550
DS	4
SWH	15723.271 Hz
ETRATES	0.239818 Hz
AQ	2.0840949 sec
RG	13004
DH	31.800 usec
DE	5.00 usec
TE	300.0 K
D1	4.0000000 sec
D11	0.0300000 sec
D12	0.0000200 sec

===== CHANNEL f1 =====

NUC1	¹³ C
P1	6.50 usec
PL1	-6.00 dB
SFO1	62.902420 MHz

===== CHANNEL f2 =====


CPBPP2	Waltz16
NUC2	¹ H
PCPD2	80.00 usec
PL2	-4.00 dB
PL12	15.00 dB
PL13	16.00 dB
SFO2	250.1310005 MHz

F2 - Processing parameters


ST	32768
SF	62.8952395 MHz
WDW	EM
SSB	0
LB	1.00 Hz
GB	0
PC	1.40

1D NMR plot parameters

CX	20.00 cm
F1P	20.076 ppm
F1	13242.91 Hz
F2P	-3.171 ppm
F2	-199.45 Hz
PPMCA	10.66246 ppm/cm
HZEN	670.61766 Hz/cm



ppm





Current Data Parameters
 NAME gohari
 EXPNO 546
 PROBNO 1

F2 - Acquisition Parameters
 Date 20130721
 Time 15:56
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG PULPROG
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 6265.664 Hz
 FIDRES 0.095606 Hz
 AQ 5.2298226 sec
 RF 181
 DW 79.800 usec
 DE 6.00 usec
 TE 300.0 K
 D1 1.0000000 sec



===== CHANNEL f1 =====
 NUC1 1H
 SI 32768
 SF 250.1300933 MHz
 WDM EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

F2 - Processing parameters
 SI 32768
 SF 250.1300933 MHz
 WDM EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



Current Data Parameters
 NAME golari
 EXPNO 547
 PROCNO 1

F2 - Acquisition Parameters
 Date 20130721
 Time 15.54
 INSTRUM spect
 PROBHD 5 mm QNP 3H/1
 PULPROG zgpg
 TD 65536
 SOLVENT CDCl₃
 NS 551
 DS 4
 SWH 15723.271 Hz
 FIDRES 0.239918 Hz
 AQ 2.0840948 sec
 RG 13004
 DW 31.800 usec
 DE 6.00 usec
 TE 300.0 K
 D1 4.0000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec



ppm

Current Data Parameters

NAME gohari
EXPNO 540
PROCNO 1

F2 - Acquisition Parameters

Date 20130721
Time 15:48
INSTRUM spect
PROBHD 5 mm GNP 1H/1
PULPROG zg
TD 65536
SOLVENT CDCl₃
NS 16
DS 2
SWH 6265.664 Hz
FIDRES 0.095606 Hz
AQ 5.2296226 sec
RG 203.2
DW 79.800 usec
DE 6.00 usec
TE 300.0 K
D1 1.0000000 SEC

===== CHANNEL f1 =====




NUC1 1H
P1 10.50 usec
PL1 -4.00 dB
SF01 250.1315371 MHz

F2 - Processing parameters

SJ 32768
SF 250.1300043 MHz
WDW EM
SSB 0
LB 0.30 Hz
BB 0
PC 1.00

1D NMR plot parameters

CX 20.00 cm
F1P 12.120 ppm
F1 3034.47 Hz
F2P -0.405 ppm
F2 -101.37 Hz
PPMCM 0.62824 ppm/cm
HZCM 156.64160 Hz/cm



ppm

Integral




Current Data Parameters
NAME gohen1
EXPO 541
PROCNO 1

F2 - Acquisition Parameters
Date 20130721
Time 13:53
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zgpg
TD 65536
SOLVENT CDCl3
NS 523
DS 4
SWH 15723.271 Hz
ETD 0.239938 Hz
AQ 2.0840948 sec
RG 13004
DW 31.800 usec
DE 6.00 usec
TE 300.0 K
D1 4.0000000 sec
D11 0.0300000 sec
D12 0.0000200 sec

===== CHANNEL f1 =====
NUC1 13C
P1 6.50 usec
PL1 -6.00 dB
SF01 62.9021320 MHz

===== CHANNEL f2 =====
CPDPG2 1H/1Hz16
NUC2 1H
FCPD2 80.00 usec
PL2 -4.00 dB
PL12 15.00 dB
PL13 18.00 dB
SF02 250.1310005 MHz

F2 - Processing parameters
SI 32768
SF 62.8952401 MHz
WDW EH
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



ppm

